<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163991</url>
  </required_header>
  <id_info>
    <org_study_id>VIB4920.P2.S3</org_study_id>
    <secondary_id>2019-003697-70</secondary_id>
    <nct_id>NCT04163991</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis</brief_title>
  <acronym>MIDORA</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viela Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viela Bio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of&#xD;
      VIB4920 (formerly MEDI4920) in adult participants with Rheumatoid Arthritis (RA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall study period will be approximately 337 days. After a screening period of up to 28&#xD;
      days, the participants will be randomized in a 1:1:1:1:1 ratio to receive intravenous dose of&#xD;
      VIB4920 and/or placebo in 5 cohorts. Participants are to be followed on their stable&#xD;
      background anti-rheumatoid arthritis (RA) therapy at least through 12 weeks (Day 85), at&#xD;
      which time rescue therapy may be instituted. All participants will be followed at least&#xD;
      through the primary (interim) analysis (Day 113), and those who have not instituted rescue&#xD;
      therapy will be followed through Day 309 to determine the duration of clinical response. The&#xD;
      primary analysis will be after all participants have completed Day 113, and the final&#xD;
      analysis will be after all participants have completed follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">December 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Day 113 in Disease Activity Score in 28 Joints Using C-reactive Protein (DAS28-CRP) (range: 1-10; higher score is worse outcome)</measure>
    <time_frame>Day 1 (Baseline) through Day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (TEAESIs)</measure>
    <time_frame>Day 1 (Baseline) through Day 309</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of VIB4920</measure>
    <time_frame>Day 1 to Day 225</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Soluble Cluster of Differentiation 40 (sCD40L) Plasma Concentration</measure>
    <time_frame>Day 1 (Baseline) through Day 309</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Anti-drug Antibodies (ADA) Titre to VIB4920</measure>
    <time_frame>Day 1 (Baseline) to Day 309</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rheumatoid Factor (RF) From Baseline to Day 113</measure>
    <time_frame>Day 1 (Baseline) through Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anti-citrullinated Protein Antibodies (ACPAs) From Baseline to Day 113</measure>
    <time_frame>Day 1 (Baseline) through Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Remission at Day 113</measure>
    <time_frame>Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Start of New Treatment for RA</measure>
    <time_frame>Day 1 (Baseline) through Day 309</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>VIB4920 Dose1 (dosing interval 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous (IV) infusion of VIB4920 Dose1 in dosing interval 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIB4920 Dose1 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV infusion of VIB4920 Dose1 in dosing interval 2 and placebo matched to VIB4920 in dosing interval 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIB4920 Dose2 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV infusion of VIB4920 Dose2 in dosing interval 2 and placebo matched to VIB4920 in dosing interval 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIB4920 Dose2 (dosing interval 4)+Placebo (dosing interval 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV infusion of VIB4920 Dose2 in dosing interval 4 and placebo matched to VIB4920 in dosing interval 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (dosing interval 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive IV infusion of placebo matched to VIB4920 in dosing interval 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIB4920</intervention_name>
    <description>VIB4920 Dose 1 or 2 will be administered intravenously per dosing interval of 1 or 2 or 4.</description>
    <arm_group_label>VIB4920 Dose1 (dosing interval 1)</arm_group_label>
    <arm_group_label>VIB4920 Dose1 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_label>VIB4920 Dose2 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_label>VIB4920 Dose2 (dosing interval 4)+Placebo (dosing interval 5)</arm_group_label>
    <other_name>MEDI4920</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered intravenously per dosing interval of 1 or 3 or 5.</description>
    <arm_group_label>Placebo (dosing interval 1)</arm_group_label>
    <arm_group_label>VIB4920 Dose1 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_label>VIB4920 Dose2 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_label>VIB4920 Dose2 (dosing interval 4)+Placebo (dosing interval 5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Principal Inclusion Criteria:&#xD;
&#xD;
          1. Male or female adults, &gt;= 18 years of age at time of informed consent.&#xD;
&#xD;
          2. Diagnosed with RA according to the European League Against Rheumatism/American College&#xD;
             of Rheumatology (EULAR/ACR) 2010 criteria &gt;= 6 months prior to screening.&#xD;
&#xD;
          3. Disease Activity Score in 28 Joints using C-reactive Protein (DAS28-CRP) &gt; 3.2 at&#xD;
             screening with &gt;= 4 tender joint count (TJC) and &gt;= 4 swollen joint count (SJC) out of&#xD;
             the 28 joints assessed for DAS28 present at screening and confirmed present at visit 2&#xD;
             prior to randomization.&#xD;
&#xD;
          4. Positive for RF and/or ACPA at screening, in accordance with criteria at the central&#xD;
             laboratory.&#xD;
&#xD;
          5. Treated with methotrexate (MTX), with or without a concomitant conventional&#xD;
             disease-modifying anti-rheumatic drug (cDMARD).&#xD;
&#xD;
          6. Agreeing to use of protocol defined contraception methods.&#xD;
&#xD;
        Principal Exclusion Criteria:&#xD;
&#xD;
          1. Prior or current inflammatory joint disease other than RA.&#xD;
&#xD;
          2. Severe interstitial lung disease.&#xD;
&#xD;
          3. Prior receipt of any biologic B-cell-depleting therapy.&#xD;
&#xD;
          4. Receipt of any anti - tumor necrosis factor alpha (TNF-α) biologic agent &lt; 8 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          5. Receipt of any biologic disease-modifying anti-rheumatic drug (bDMARD) with a&#xD;
             mechanism of action other than direct TNF- α blockade, &lt; 12 weeks or &lt; 5 half-lives of&#xD;
             the drug prior to screening.&#xD;
&#xD;
          6. Injectable corticosteroids or treatment with &gt; 10 mg/day dose of oral prednisolone or&#xD;
             equivalent within 4 weeks prior to screening.&#xD;
&#xD;
          7. Previous treatment with anti-CD40L compounds at any time before randomization.&#xD;
&#xD;
          8. Hepatitis B, hepatitis C, or human immunodeficiency virus infection.&#xD;
&#xD;
          9. Pregnant or lactating or planning to get pregnant during the duration of the study.&#xD;
&#xD;
         10. Evidence of active tuberculosis (TB) or being at high risk for TB.&#xD;
&#xD;
         11. History of more than one episode of herpes zoster in the 12 months prior to screening&#xD;
             or any opportunistic infection in the 12 months prior to screening, excluding&#xD;
             localized mucocutaneous candidiasis.&#xD;
&#xD;
         12. Receipt of live vaccine or live therapeutic infectious agent within the 4 weeks prior&#xD;
             to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Barbieri, MD</last_name>
    <role>Study Director</role>
    <affiliation>Viela Bio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandalia</city>
        <state>Ohio</state>
        <zip>45377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nadarzyn</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siedlce</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <state>Małopolskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elblag</city>
        <state>Warmińsko-mazurskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>VIB4920</keyword>
  <keyword>MEDI4920</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

